Zetiq completes first arm of cervical cancer study
The goal of the trial was to demonstrate and measure the ability of Zetiq’s technology to accurately diagnose the presence of cervical cancer cells and the stage of
Amberstone Biosciences has signed a partnership and licence agreement with Shanghai Henlius Biotech for conditionally activated T-cell engager candidates to treat solid tumours.